WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion
  • Wealthtech

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Executive Branch Updates
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • FDA Regulatory, Healthcare, and Consumer Products
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • National Security and Trade
  • Payments
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting
Lily Zhang
Patent Agent
Patents and Innovations
New York
lzhang@wsgr.com

D212-453-2808

Download vCard
Open PDF

Dr. Lily Zhang is a patent agent in the New York office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patents and innovations group. Her practice focuses on patent prosecution across multidisciplinary fields, including immunology, microbiology, genomics, bioinformatics, AI/machine learning, molecular diagnostics, and related technologies.

Prior to joining the firm, Lily completed her doctoral degree in computational biology at New York University. Her Ph.D. dissertation focused on investigating how the gut microbiome affects immune cells in cancer immunotherapy patients using computational methods. She was also a licensing intern at New York University's technology transfer office, where she worked on technology marketing.

Experience

Dr. Lily Zhang is a patent agent in the New York office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patents and innovations group. Her practice focuses on patent prosecution across multidisciplinary fields, including immunology, microbiology, genomics, bioinformatics, AI/machine learning, molecular diagnostics, and related technologies.

Prior to joining the firm, Lily completed her doctoral degree in computational biology at New York University. Her Ph.D. dissertation focused on investigating how the gut microbiome affects immune cells in cancer immunotherapy patients using computational methods. She was also a licensing intern at New York University's technology transfer office, where she worked on technology marketing.

Education
  • Ph.D., Computational Biomedicine, New York University, 2026
  • B.A., Molecular Biology and Biochemistry, Rutgers University-New Brunswick, 2020
Admissions
  • U.S. Patent and Trademark Office
Credentials
Education
  • Ph.D., Computational Biomedicine, New York University, 2026
  • B.A., Molecular Biology and Biochemistry, Rutgers University-New Brunswick, 2020
Admissions
  • U.S. Patent and Trademark Office

Select Publications

  • Co-author, "mRNA COVID-19 vaccine elicits potent adaptive immune response without the persistent inflammation seen in SARS-CoV-2 infection," iScience, 2023
  • Co-author, "Gut microbiome dysbiosis in antibiotic-treated COVID-19 patients is associated with microbial translocation and bacteremia," Nature Communications, 2022
  • Co-author, "C. Elegans Nuclear RNAi Factor SET-32 Deposits the Transgenerational Heritable Histone Modification, H3K23me3," ELife, 2020
Insights

Select Publications

  • Co-author, "mRNA COVID-19 vaccine elicits potent adaptive immune response without the persistent inflammation seen in SARS-CoV-2 infection," iScience, 2023
  • Co-author, "Gut microbiome dysbiosis in antibiotic-treated COVID-19 patients is associated with microbial translocation and bacteremia," Nature Communications, 2022
  • Co-author, "C. Elegans Nuclear RNAi Factor SET-32 Deposits the Transgenerational Heritable Histone Modification, H3K23me3," ELife, 2020
Focus Areas
  • Artificial Intelligence and Machine Learning
  • Biotech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Intellectual Property
  • Life Sciences
  • Patents and Innovations
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.